The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | Genomic pathway of gut microbiome predicts efficacy of nivolumab in advanced GC
Yu Sunakawa, MD, PhD, St. Marianna University School of Medicine, Kawasaki, Japan, provides an update on the DELIVER trial, an observational study evaluating nivolumab in patients with advanced gastric cancer (GC) with the aim of investigating whether genomic information the gut microbiome serves as an accurate predictor of response to nivolumab in advanced gastric cancer. The results of the study suggest that bacterial invasion of epithelial cell pathways in the gut microbiome may represent a novel biomarker for treatment with PD-1 checkpoint blockade in patients with advanced gastric cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
